Trevi Therapeutics Inc (TRVI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2018 | 06-2018 | 03-2018 | 12-2017 | |
| Cash Flows From Operating Activities | ||||
| Net Income | -14,563 | -8,909 | -4,051 | -12,860 |
| Depreciation Amortization | 70 | 66 | 45 | 2,185 |
| Accounts receivable | -70 | -38 | -18 | N/A |
| Accounts payable and accrued liabilities | 124 | 180 | 109 | N/A |
| Other Working Capital | -1,470 | -2,257 | -892 | 722 |
| Other Operating Activity | 2,352 | 1,394 | 853 | 1,978 |
| Operating Cash Flow | $-13,557 | $-9,564 | $-3,954 | $-7,975 |
| Cash Flows From Investing Activities | ||||
| PPE Investments | -66 | -67 | -57 | -13 |
| Investing Cash Flow | $-66 | $-67 | $-57 | $-13 |
| Cash Flows From Financing Activities | ||||
| Debt Repayment | -4,813 | -4,812 | -2,063 | N/A |
| Common Stock Issued | 13 | 13 | 13 | N/A |
| Other Financing Activity | 9,937 | -532 | 0 | 21,722 |
| Financing Cash Flow | $5,137 | $-5,331 | $-2,050 | $21,722 |
| Beginning Cash Position | 22,020 | 22,020 | 22,020 | 8,286 |
| End Cash Position | 13,534 | 7,058 | 15,959 | 22,020 |
| Net Cash Flow | $-8,486 | $-14,962 | $-6,061 | $13,734 |
| Free Cash Flow | ||||
| Operating Cash Flow | -13,557 | -9,564 | -3,954 | -7,975 |
| Capital Expenditure | -66 | -67 | -57 | N/A |
| Free Cash Flow | -13,623 | -9,631 | -4,011 | -7,975 |